Baloxavir marboxil (BXM) represents a promising advance in antiviral chemotherapies for influenza infections. Identification of transmissible BXM-resistant strains in Japan may hit pause on widespread adoption of this therapy and could lead to revision of surveillance practices for emerging viruses.
- Karen A. Kormuth
- Seema S. Lakdawala